Evidence map›Paper›PMID 40815609›Full record

Trial reportOncoimmunology2025

A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages.

Katherine M Bever, Sarah M Shin, Jennifer N Durham, Hanfei Qi, Alexei Hernandez, Erin M Coyne, Nicole E Gross, Soren Charmsaz, Jayalaxmi Suresh Babu, Diana Carolina Vargas Carvajal and 14 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Neutrophils in cancer.Nature reviews. Cancer · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Katherine M BeverSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Sarah M ShinSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Jennifer N DurhamSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Hanfei QiSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Alexei HernandezSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Erin M CoyneSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Nicole E GrossSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Soren CharmsazSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Jayalaxmi Suresh BabuSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Diana Carolina Vargas CarvajalSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Rohan VermaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Yanyi SunSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Zhehao ZhangSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Xuan YuanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Courtney D CannonSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Sarah N HughesDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Sarah MitchellSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Madeline FiglewskiSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
James M LeathermanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Hao WangSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Robert A AndersSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Elizabeth M JaffeeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Dung T LeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Won Jin HoSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-2644-5086

Funding

Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A. · 2021 to 2025
$12.7M
Mass Cytometer CyTOF XT for Single-Cell BiologyS10OD034407 · OD · JOHNS HOPKINS UNIVERSITY · PI HO, WON JIN · 2024 to 2024
$499k
Immunophenotype Integration for Monitoring T Cell Dynamics in Pancreatic CancersR21CA264004 · NCI · JOHNS HOPKINS UNIVERSITY · PI HO, WON JIN · 2021 to 2021
$421k
NCI NIH HHS P01 CA247886NCI NIH HHS R21 CA264004NIH HHS S10 OD034407
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and myeloid-rich microenvironment that confer resistance to immunotherapies. Previous studies demonstrated that disrupting the immune-stroma CXCR4-CXCL12 axis facilitates T cell recruitment and mobility to collaborate with anti-PD1/PD-L1 therapy. We sought to test the clinical viability of this immunotherapeutic strategy. 21 patients with metastatic PDAC were enrolled and treated in a phase 2 trial evaluating the effects of the plerixafor/AMD3100 and cemiplimab. Primary endpoint was objective response rate. Blood and tissue biospecimens were collected for correlative analyses. Parallel mouse studies were used to determine potential mechanisms of resistance. Treatments were well-tolerated, but only two patients demonstrated a best response of stable disease. Correlative analyses confirmed significant mobilization of immune cells into circulation as well as increased immune infiltration into the tumor. High-parameter imaging revealed higher levels of CD8

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalMacrophagesPancreatic NeoplasmsProgrammed Cell Death 1 ReceptorReceptors, CXCR4T-LymphocytesAgedAnimalsBenzylaminesCyclamsFemaleHeterocyclic CompoundsHumansImmune Checkpoint InhibitorsMaleBenzylaminesCXCR4 protein, humanCyclamsHeterocyclic CompoundsImmune Checkpoint InhibitorsPDCD1 protein, humanplerixaforProgrammed Cell Death 1 ReceptorReceptors, CXCR4Cancer immunologycheckpoint immunotherapyCXCL12CXCR4mass cytometrypancreatic cancertumor microenvironment

Identifiers

PMID40815609
PMCPMC12360203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.